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Personal Reflection – Johannes Suppanz (33877)
4
BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care
Hard Skills
Analytical skills to face comprehensive issues, such as markets, companies and business models, in
a more structured and efficient manner.
Which har /sof  skills did y u develop through the project?1
Soft Skills
Financial Modeling of an integrated Leverage Buyout Excel Model connecting Balance Sheet,
Income and Cash Flow Statement including the respective forecast.
Improvement of ability to produce compromized content in a clear manner that is easy to understand
for the reader.
Professional communication and effective discussion within a team to solve issues time efficient and
to focus on the relevant topics.
Improvement of Time Management to meet given deadlines with a steady level of time consumption
per day.
How to get information from industry experts, including the first approach of the expert via mail,
LinkedIn or calls, interview preparation as well as the actual interview.
What would you change in your individual or team approach if you had to do a similar project?2
Individual Approach Team Approach
Talk to even more industry experts right from the beginning, which helps to address certain issues I
might not consider myself.
General
Dealing with extreme workload without losing the focus on the relevant things.
What skills did the Masters’ program gave you so you could be prepared for this kind of project?3
Private Equity Course
By choosing the corporate finance area of expertise the focus of my master was on deal related 
topics which helped me to have  more comprehensive view on private equity cases.
Understanding the private equity industry especially how it operates, its value-creation strategies,
terminology and the key aspects to consider when acquiring.
Spend more time besides the project to foster the relationship between each member.
Have stricter internal deadlines and discuss the produced content. This is especially true in the
beginning of the project to better understand the industry and the company's business model.
How to model an Leverage Buy Out in Excel including the practical approach of a valuation using
several valuation methods.
Due to the course assignment I knew beforehand what an investment committee paper is and what I




Strong market revenue growth as well as highly leverageable internal capabilities make 
BioTelemetry an attractive target for an LBO
6
Key Reasons for the Deal
Attractive and growing markets
Market leadership in Remote Cardiac 
Monitoring services 
Combined with strong capabilities in all 
operating business units, this ensures 
vast potential for value creation
• Market Growth: The market for Cardiac
Monitoring is expected to grow at a CAGR of
5.8% until 2026.
• Market Drivers: An increasing and aging
population, an increasing healthcare spending
as well as the shift from volume- to value-
based reimbursement.
Remote Cardiac Monitoring Glucose MonitoringClinical Trial Services
• Market Growth: The market for Glucose
Monitoring is expected to grow at a CAGR of
6.2% until 2026.
• Market Drivers: An increasing and aging
population, an increasing healthcare spending
as well as an increasing prevalence of
malnutrition and obesity.
• Market Growth: The market for Clinical Trial
Services is expected to grow at a CAGR of
9.9% until 2026.
• Market Drivers: An increasing tendency
towards the outsourcing of major parts of
research activities by Pharmaceutical, Biotech
and other companies.
• Market Leadership: BioTelemetry is the
leading provider of remote cardiac monitoring
devices and services in the most attractive
market globally, the US.
• Technological Advantages: Leadership in
this fragmented market is based on the wide-
ranging product and service offering as well as
on BioTel’s technological advantages,
particularly with its patent-secured Extended
Holter and MCOT.
• Geneva Software Platform: New cloud-
based platform for implantable cardiac device
monitoring data completes BioTel’s service
offering, having an impact on patient care and
workflow of physicians, and will further
support market leadership.
• Diversification: BioTel’s Glucose Monitoring
business, is an addition to the current product
portfolio and the commitment to innovate
connected health services.
• Technological Advantages: BioTel’s device
provides clear technological edges to the
existing competition with the first FDA-cleared,
cellular-enabled glucose meter consolidating
patient data in the cloud, making it easily
accessible.
• Health Management Leader: The glucose
monitor features the ability to consolidate data
from other connected health devices, uniquely
positioning the company to move beyond
diabetes to the management of chronic
diseases.
• Stable Revenue Stream: BioTel’s Research
business is an attractive source of additional
revenue in the enormous market for Clinical
Trial Services.
• Therapeutic Expertise: The experience in
cardiovascular testing, technological
capabilities and operational synergies with the
Remote Cardiac Monitoring business provide
highly demanded expertise to outsourcing
research sponsors.
• Strong Value Proposition: The recent
addition of imaging capabilities to become an
integrated cardiac and imaging testing
platform will enable BioTel to deliver even
greater value to the customers.
BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care 
Operating across three highly attractive and growing markets, the target company is well-positioned to sustain and grow its technological leadership, which is strongly secured through intellectual
property covering its key devices, algorithms and reporting standards, particularly in its major business unit offering Remote Cardiac Monitoring services.
Strong historic financial performance: BioTel can also look at strong historic financial performance with revenue growing for 29 consecutive quarters. These robust financials, including its stable
Operating Cash Flow and significantly growing Unlevered Free Cash Flow, make the target company highly leverageable.
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Market Definition
Remote Cardiac Monitoring 
Clinical Trial Services 
Glucose Monitoring
January 2020
Cardiac Monitoring is the observation of the medical condition
of the heart or specific heart-related parameters of a patient,
either inpatient (stationary) or outpatient (remote), over a specific
time period.
This paper focuses on Remote Cardiac Monitoring. RCM
allows patients with suspected cardiac arrhythmias or at risk of
developing arrhythmias to use mobile medical devices,
technology, and services to gather patient-generated health data,
particularly electrocardiograms, and make it accessible to health
professionals.
Industry Overview – Market Definition
BioTelemetry is currently active across the markets for Remote Cardiac Monitoring, Clinical Trial 
Services and Glucose Monitoring




The global health economy is driven by large demographic, economical and technological trends:
Major Industry Trends
Increasing and aging population: Population is increasing and while people aged 65 or above accounted for less than 6.4% in 1993, the same group accounted for more than 8.8% in 20181. This
trend is expected to continue over the next 25 years2.
Increasing global healthcare spending: Along this demographic shift, global healthcare spending is expected to increase by 30% to $10tn from 2017 to 2022. By far the largest amount is spent in
North America with an expected $4tn, whereas the largest growth is expected to come from Asia3.
Shift from volume- to value-based reimbursement: Healthcare systems worldwide will need to innovate and embrace clinical research, new technologies and risk models to potentially shape
affordable, high-quality healthcare solutions for the future; this shift to value-based care appears to be most active in the United States3.
Increasing investment in R&D: Due to the rapidly increasing prevalence of chronic diseases, Pharmaceutical and Biotechnology companies will increase their spending in the R&D domain. In order
to reduce costs and to ensure regulatory compliance, much of these growing investments are expected to be outsourced to clinical research providers.
Remote Cardiac Monitoring Clinical Trial Services Glucose Monitoring
1
Glucose Monitoring is the observation of the concentration of
glucose in the blood, which is typically performed by the patient
individually. There are two main procedures, Blood Glucose
Monitoring and Continuous Glucose Monitoring.
This paper focuses on Blood Glucose Monitoring with an
excursion into Continuous Glucose Monitoring. BGM allows
patients with diabetes or similar chronic diseases to use mobile
medical devices, technology, and services to individually perform
blood tests and monitor their blood glucose level.
Due to increasing time pressure and costs, companies in the
medical space (e.g. Pharma, Biotech) are increasingly
looking to outsource critical and cost-intensive functions,
including Research & Development.
This paper focuses on research services during Clinical Trial.
Clinical Trial Services refer to all pre-approval research services
on drugs or devices that are done in humans and outsourced to
Contract Research Organizations. CROs are companies offering
these research services on contract.
32
Research & Development
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Industry Overview – Remote Cardiac Monitoring
Remote Cardiac Monitoring provider promote their products to physicians, deliver the service and 
perform services to the patient and get reimbursed by insurances
1
Remote Cardiac Monitoring is the outpatient monitoring of patients who are suspected to suffer
from cardiac arrhythmias. Monitoring devices differ in application period, reimbursement rate
as well as continuity of monitoring. The market dynamics are described in the following:
Sales and Marketing
• Physicians are the primary (only) “distributor” of remote cardiac monitoring devices to
the end user (i.e. the patient, due to the required prescription).
• Sales to physicians are still largely traditional and dependent on relationships,
conferences, fairs and one-to-one sales.
• Key requirements are that the medical devices and services are reimbursable and easy-to-use.
Consultation and Prescription
• Patients consult their physician in case of any symptomatic irregularities, such as faint, heart
flutter or for their regular health check.
• If the physician suspects heart-related issues, one of the devices presented will be prescribed to
monitor the heart rhythm of the patient over time.
Fulfillment
• After the doctor’s prescription, the Remote Cardiac Monitoring provider sends the product
directly to the patient. For the accurate installation of Traditional Holter devices, a physician
might be required.
Reimbursement
• After fulfillment, public or private insurances perform payment based on reimbursement rates




• This device is typically the first step to continuously monitor the heart rhythm over
shorter periods.
• Application: 24-48 hours (Traditional) or 2 weeks (Extended).
• Reimbursement: ~$50.
Holter
• In order to monitor and store data, it requires activation by the patient or by an
abnormal heart rhythm. Hence, devices do not record continuously.
• Application: Up to 30 days.
• Reimbursement: ~$250.
Event
• MCOT enables continuous transmission of data from the device to monitoring centers
or physicians.
• Application: Up to 30 days.
• Reimbursement: ~$800.
MCOT
ILR • This is a small implantable device that gets placed under the skin in the upper chest
area and continuously records heart rhythms.
• Application: Up to 5 years.
• Reimbursement: Case-to-case basis (carrier-priced).
Market Dynamics
Other market players include2:
• Suppliers provide necessary components to manufacturers. The number of suppliers is limited
and the process to qualify as a supplier is lengthy, which increases the supplier power.
• Manufacturers are subject to extensive FDA regulation. These entities are usually subject to
high R&D expenses. Manufacturers are usually the same entity as RCM providers.
• Regulatory bodies, such as the FDA govern the manufacturing, labeling, promotion,















Overview of Remote Cardiac Monitoring Devices1:
Notes: 1See Appendix 1-6; 2See Appendix 7. Sources: BioTelemetry, Expert Interviews











Cardiovascular diseases are one of the leading causes of mortality worldwide. In the US alone,
more than 17.3mn annual deaths have been attributed to heart-related diseases, such as
cardiomyopathy. Remote Cardiac Monitoring is focused on the diagnosis and monitoring of cardiac
arrhythmias or heart rhythm disorders in view of the prevention and treatment of such diseases.
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US RoW
The Remote Cardiac Monitoring market is highly fragmented with several large and many small
companies, which fight for relevant market share in this attractive market. In addition to the high





BioTel iRhythm Other Device + Service Providers Device Providers only
Industry Overview – Remote Cardiac Monitoring
Remote Cardiac Monitoring realized continuous growth in the past and is expected to reach an 
attractive value of $8bn by 2026, of which the US will account for 27%
Remote Cardiac Monitoring Market 2018-2026, In $bn Competitive Landscape




• Driven by the increase in the prevalence of heart diseases and the reliability of Remote
Cardiac Monitoring in the detection of life-threatening arrhythmias, the global market for
Remote Cardiac Monitoring is currently valued at above $5bn and is expected to





























• The largest player offering devices and services is BioTel. Only few companies can
be classified as direct competition with similar propositions (See Appendix 8).
• The second largest player is iRhythm. Its revenue, however, is expected to decrease as
its provisionary reimbursement codes will be transitioned to lower, permanent ones. As a
result, future rates are expected to drop by up to 50%2. Other direct competitors include
SHL Telemedicine, BardyDx, Preventice, and CardioDiagnostics.
• Besides the abovementioned direct competition, the market comprises many other
companies, including large healthcare conglomerates, such as Abbott Laboratories,
Boston Scientific Corporation, and Medtronic, distributing the Remote Cardiac
Monitoring only without the addition of any services.
• Particularly large healthcare conglomerates pose strong competition due to their





• The growth can be attributed to major trends, such as an increasing and aging
population as well as an increasing healthcare spending.
• In larger and advanced economies, the shift from volume- to value-based
reimbursement is expected to further drive the growth of telemedicine solutions, as it will
enable more efficient healthcare spending (e.g. through fewer in-person visits).
• In addition, technological advancements and product innovation are expected to
increase awareness for heart-related diseases (e.g. Apple Heart Study) and to drive the
development of more efficient monitoring devices.
• The US accounted for $1.4bn (~27% of global revenues) in 2018, which makes it the
largest geographical market for Remote Cardiac Monitoring followed by Europe. While the
US is expected to retain its leadership position, the highest growth is expected to come
from the Asia-Pacific region with strong growth in China in particular.
• M&A activities are highly attractive, as they offer companies an opportunity to enter
new markets fast without dealing with regulatory issues, such as BioTel's acquisition
of Geneva (2019), a cloud-based software firm, and LifeWatch (2017), a provider of
technology for MCOT devices.
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Industry Overview – Clinical Trial Services
If awarded with the research, Contract Research Organizations take over the conduct of clinical 
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CRO Engagement Models, Now and Then: 
Oncology • Oncology deals with the prevention, diagnosis, and treatment of cancer.
• Due to its importance and the vast revenue potential of cancer treatment drugs,
oncological products are at the top of the list in R&D.
Cardio
• Cardiology deals with disorders of the heart and parts of the circulatory system.
• Due to the rise of cardiovascular diseases as well as the importance of the
heart and circulatory system, cardiological expertise is essential for clinical
trials.
Neuro
• Neurology deals with disorders of the brain and nervous system.
• Due to the rise of neurology to become the third largest discipline for patient
care, many CROs offer extensive expertise or specialize in neurological
methodologies.
Genetics • Genetics with the study of genes, genetic variation, and heredity in organisms.
• Due to the increasing number of clinical trials in gene therapy, partly driven by












• After the initial phases of drug discovery and pre-clinical research are concluded, outsourcing
Pharma and Biotech companies tender required Clinical Trial Services and award the
contract to the winning Contract Research Organization.
• While the engagement and associated responsibilities between PharmaBio companies and
CROs have historically been widely separated, it is expected that the trend towards a more
hybrid approach continues, meaning that the CROs are increasingly involved in the early
phases of planning the clinical trial (See Graph at the bottom).
Conduct of Clinical Trial
• CROs plan, set-up and conduct the clinical trial; this includes the recruitment or retention of
patients, which is considered to be one of the major challenges and a common reason for
delayed starts of clinical trials.
• Depending on the drug or medical device to be developed, the CRO applies methodologies
from different therapeutic areas; the most required therapeutic expertise are in oncology,
cardiology, neurology and virology (See Overview to the left).
Coordination with FDA
• Typically, the CRO coordinates all regulatory issues with the FDA that are required for the
approval of the drug or medical device and that are associated with the contracted research they
are conducting for Pharma and Biotech companies.
Approval of Drug or Medical Device
• If the research is successful, the FDA grants approval to mass market the drug or device to
the PharmaBio companies.
• The CRO has no legal claim to the approval as it is only conducting contracted research for
another party.
Most Required Therapeutic Expertise in Clinical Trials:
Sources: BioTelemetry, Expert Interviews
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Pharmaceutical and Biotechnology companies, among others, increasingly outsource their research
activities to specialized companies, so-called Contract Research Organizations. Clinical Trial
Services, next to Pre-Clinical and Post-Clinical Services, account for the vast majority of these
outsourcing activities.
The market for Clinical Trial Services is highly fragmented and competitive. Particularly due to the
large amount of CROs, there is fierce competition for both customers and clinical trial patients. This
competitiveness can cause periods of strong price competition to land the contract for specific
clinical trials and hence increasing pressure on profitability.
Industry Overview – Clinical Trial Services
The Clinical Trial Services market is expected to reach more than $53bn by 2026, mainly driven by 
the increasing spending and outsourcing of R&D by Pharmaceutical and Biotech firms




• The global market for Clinical Trial Services is valued at $25bn in 2018 and is
expected to grow at an impressive CAGR of 9.9% during the period from 2018 to 2026.
• This includes all research services conducted by Contract Research Organizations during





























• Competing businesses include traditional CROs, the in-house research and
development departments of PharmaBio companies, universities, and teaching
hospitals. Among the traditional CROs, there are several hundred small, limited-service
providers, several medium-sized firms and only a few full-service companies with global
capabilities.
• The largest five players, however, account for 45% of the global market. These
players include multinational CROs – IQVIA (formerly Quintiles), LabCorp, Parexel, PRA




• The US accounted for $8.7bn (~35% of global revenues) in 2018, which makes it the
largest geographical market for Clinical Trial Services followed by Europe.
• While the US is expected to retain its leadership position, the highest growth is expected
to come from developing countries.
• Larger players have followed the trend of M&A to enhance full-service capabilities and
international reach, while mid-sized and smaller CROs are more and more focusing on
niche sectors and a more personalized approach to their sponsors.
• The largest consolidating transaction in the previous years was the merger of IMS Health
and Quintiles in 2016 to form IQVIA, now the world’s largest CRO, through a deal
valued at more than $13bn.
• In addition, the market saw many smaller deals intending to acquire expertise in a
specific area.
• Future revenue growth depends upon factors, such as growth in allocated R&D
spending, which is driven by the growing patient population and the demand for new,
innovative and effective drugs and medical devices.
• In addition, Pharma and Biotech industries are increasingly recognizing the difficulties of
the stringent approval processes by regulatory bodies (i.e. the FDA) and hence the
importance of scale and therapeutic expertise to accelerate the introduction of
drugs and medical devices in the market in a cost-effective manner, which will further
propel the outsourcing of clinical trials to CROs2.
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Notes: 1Assuming two test stripes per day. Sources: CMS, Expert Interviews
Industry Overview – Glucose Monitoring
The patient decides upon the glucose monitoring device, while one of the main criteria is its 
reimbursement by the insurance
3
Patient
Blood Glucose Monitoring allows patients with diabetes or similar chronic diseases to use mobile
medical devices, technology and services to individually perform blood tests and monitor their blood
glucose level. The market dynamics are described in the following:
Marketing
• Provider of blood glucose monitors approach patients via several online channels and adds
(e.g. Facebook, Google, and online forums) as well as diabetes conferences and fairs.
• Patients decide if reimbursement is granted and based on recommendation which devices to use.
Switching costs are not significant and patients might change device during diabetes life.
Promotion
• BGM provider must promote their products to insurances to ensure that patients get
reimbursed. Only a few patients will afford non-reimbursable devices.
• Usually, insurances ask for more effective products, that result in cost-savings for the
insurance.
Recommendation
• Once the BGM devices are reimbursable, insurances promote the product to the physicians.
Consultation and Prescription
• If the physician diagnoses the patient with diabetes, he/she prescribes the device, that is
reimbursable for the patient. Hence, he/she forwards the recommendation of the insurance.
Sales
• In most cases, devices are sold via third-party distributors instead of direct sales. These
distributors can be online pharmacies or wholesalers, such as Walmart.
Reimbursement
• Based on previous negotiations between insurances and BGM providers, the patient gets






























Overview of Glucose Monitoring Devices:
• The traditional “finger prick” BGM system measures the glucose level at the time of
the test.
• On average, patients perform two tests per day (equals two glucose values per day).
• Depending on the patients’ needs, tests are performed up to seven times a day.
• Reimbursement: ~$20 for device + ~$24 per month for test stripes1.
• CGM devices do not require the patient to perform blood tests themselves.
• These devices perform a test every 5 minutes, which results in 288 tests a day. It is
expected, that CGM will replace BGM in the long term.
• CGM devices are connected to a patch, which holds on the body for up to 14 days.
• Reimbursement: ~$70 for device + ~$70 per month for patches.
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Other market players include:
• Suppliers provide necessary components to manufacturers. The number of suppliers is limited
and the process to qualify as a supplier is lengthy, which increases the supplier power.
• Manufacturers are subject to extensive FDA regulation. These entities are usually subject to
high R&D expenses.
• Regulatory bodies, such as the FDA govern the manufacturing, labeling, promotion,
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According to the WHO, diabetes was the 7th leading disease, causing death in 2016. Hence, remote
glucose monitoring devices can be essential for patients’ survival to balance their blood glucose
levels.







2018 2019E 2020E 2021E 2022E 2023E 2024E 2025E 2026E
US RoW
The market for Remote Glucose Monitoring is highly fragmented, but largely dominated by
multinational companies. Overall, the five largest players, of which three are considered large
healthcare conglomerates, accounted for ~65% of the global market volume in 2018. The rest of the
market comprises numerous mid- to small-sized enterprises.
Industry Overview – Glucose Monitoring
The Glucose Monitoring market is expected to further grow to more than $20bn by 2026, mainly 
driven by Continuous Glucose Monitoring solutions




• The global market for Glucose Monitoring is valued at $12.6bn in 2018 and is
expected to grow at a healthy CAGR of 6.2% to $20.4bn by 20262.
• Despite BGM being the larger market today, it is expected, that CGM will gain traction in





























• The global market leader is Medtronic with approximately $2.5bn in revenues in
20184, followed by Abbott Laboratories with almost $2.0bn and strong double-digit
growth5. Abbott's main product in its Diabetes Care division is the “Freestyle Libre”, an
innovative CGM device. The third largest player with also almost $2.0bn in revenues
is Roche.
• Besides these large companies, the market is very fragmented with several players
with smaller market share, such as BioTel. They benefit from the growth of the




• The growth in the market can be attributed to major trends, such as an increasing and
aging population. In addition, the increasing prevalence of obesity and sedentary
can be observed across the globe.
• Furthermore, rapid technological advancements are expected to drive the
awareness and availability of glucose monitoring among people with diabetes.
• The development of CGM devices, which are more expensive than traditional BGM
devices, will positively impact the market size as the simplicity of the device will prevent
inaccurate use leading to higher trust by the patients.
• The US accounted for almost $5bn (~38% of global revenues) in 2018, which makes it
the largest geographical market for Glucose Monitoring followed by Europe.
• Untapped markets like the Middle East and Africa, however, show that the Glucose
Monitoring market has vast opportunities in different regions.
• M&A is highly attractive for Remote Glucose Monitoring companies. On one hand, there
are many innovative companies, which are an attractive target to acquire new
technology. On the other hand, companies are spread around the globe, enabling buyers
to enter new geographic markets without dealing with authorities to launch their product
on another market or to vertically integrate cross-border distribution channel6.
• Dexcom, for example, acquired Nintamed, a German distribution company which should
help Dexcom to forward in its mission to improve access to its CGM technologies
globally7.






4. Mobile Cardiac Monitoring
5. Implantable Loop Recorder
6. Pacemaker
Appendix 1 – Traditional Holter
Traditional Holter devices have the shortest monitoring period and the lowest diagnosis yields 
among cardiac monitoring devices
Description
• A Traditional Holter monitor is a small electrocardiogram, portable, and wearable device that keeps
track of the patient's heart rhythm. It keeps the record of the heart rhythm typically over a 24-72-hour
period, and the patient keeps a diary of activities and symptoms.
• It is a painless and noninvasive prescription. It is also considered as a low-cost, low-risk option.
Prescription
• A Traditional Holter monitor test is usually performed after a traditional test to check the patient’s heart
rhythm, especially if the electrocardiogram does not give the doctor enough information about the
heart's condition.
• It is usually the first line of defense of extra-monitoring prescribed by doctors and physicians and it is
classified as a short cardiac monitoring method. If the Traditional Holter monitoring does not capture
the irregular heartbeat, physicians may prescribe additional and more time demanding monitoring
services.
Cardiac Data Recording Process
• The Traditional Holter device monitors continuously the heart rhythm during the monitoring period.
When prescribed, physicians should place electrodes that sense the heartbeat on the patient’s chest.
These electrodes are then connected to the device. Besides having the device recording the
heartbeat, the patient is asked to keep a diary of all activities and symptoms while using the device.
While monitoring the heart’s rhythm, the patient may do its normal activities.
• Once the monitoring period is over, the patient should return the device to doctors/physicians along
with the diary. While recording, cardiac data is stored in a flash memory card and then is transferred to
the analysis conducted by the doctor/monitoring centers. Data is then compared and correlated to the
patient’s activities and symptoms during the monitoring period.
Diagnosis Yield1
• Yields are usually low, ranging from 5-18%. These are the lowest yields among Event and Mobile
Cardiac Monitoring ones.
• The main reason for these yields is the short cardiac monitoring period, in which most symptoms may
not reappear in the 24-72 hours during which the device is connected.
Notes: 1Diagnosis Yield: The proportion of patients in whom the medical technique yielded a definitive diagnosis out of the total number of patients that have received the diagnostic procedure. Sources: BioTelemetry Website & Documents; Mayo Clinic;
Digirad Website
Traditional Holter monitoring device
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Appendix 2 – Extended Holter
Extended Holter are prescribed in case the Traditional Holter results are not conclusive as these 
devices continuously record and store heartbeats
Description
• The Extended Holter is a device that continuously records and stores heartbeats for a period up to 14
days, without requiring battery changes.
• It has two key elements: the patch and the sensor. It is wires-free. The sensor collects and transmits
cardiac data to monitoring centers. Besides having the recording cardiac data, the patient should also
fill the diary with its symptoms.
• Given its recent development, it is still a more expensive solution than the Traditional Holter.
Prescription
• It is usually prescribed when Traditional Holter results are not conclusive. The Extended Holter device
is a more accurate and effective method of detecting arrhythmias when compared to the Traditional
Holter.
• It is classified as medium-short cardiac monitoring method. It also offers a less invasive and more
convenient monitoring method than long-term devices, such as Implantable Loop Recorders.
Cardiac Data Recording Process
• This device can be setup up by doctors or by the patient himself. Patients should place the sensor into
the patch and then place the patch in the patient’s chest, as illustrated. If needed, the patch may be
replaced during the monitoring period. There is no need for replacing the device’s battery.
• Since its setup, the Extended Holter sensor continuously records and stores cardiac data. Whenever
the patient feels a heart-related symptom, he/she should double-tap the middle of the sensor to record
the symptom. He/she should also write that symptom in the diary.
• Cardiac data is transmitted via cellular coverage to the doctors or monitoring centers. This data is
then analyzed, and cardiac reports are elaborated.
Diagnosis Yield
• Yields are greater when compared to Traditional Holter devices. In some studies, Extended Holter
yields may reach up to 60%.
• The main reason for this improvement is the longer monitoring period, in which the probabilities of
recording patients’ abnormal symptoms are higher.
Sources: BioTelemetry Website & Documents; Digirad
Extended Holter monitoring device
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Appendix 3 – Event Recorder
Event recorders are activated through patient’s symptoms are offer a monitoring period up to 30 
days
Description
• An Event Recorder is a portable device that offers an arrhythmia detection algorithm that detects and
automatically transmits asymptomatic and symptomatic events, including: atrial fibrillation,
tachycardia, bradycardia and pause. It records the same information as an EKG but for longer periods
of time, which can range up to 30 days.
• Event devices do not record continuously. They record when the patient activates them or when an
abnormal cardiac event activates the recorder. There are two main types of event monitors:
• Symptom Event Recorder: When activated, it only records the information from the heart’s electrical
signal for the next few minutes after being activated.
• Memory Looping Recorder: When activated, it records the information from a few minutes before
the device was activated and also minutes after. So data from before, during and after the symptom is
captured.
Prescription
• The Event recorder is used to record symptoms that are not always detectable when doing an EKG
exam or when prescribing a Traditional Holter device. It is usually the next line of defense after
prescribing the Traditional Holter. It is classified as a long cardiac monitoring method.
Cardiac Data Recording Process
• The device is composed by a small recorder that stores cardiac data and by electrodes connected to
the patient’s chest. These electrodes should be placed in specific locations of the patient’s chest, as
illustrated. Battery and electrodes may have to be changed during the monitoring period.
• The monitor is designed to detect and record specific heart symptoms. When the patient has a
symptom, he/she can also activate the recording activity by pressing a button on the monitor.
• Event data is transmitted, either through the automatic transmission of event data with wireless event
monitors or through the telephonic transmission of stored event data with traditional event devices.
This data is then analyzed by cardiac technicians/doctors to identify possible arrhythmias.
Diagnosis Yield
• Yields vary significantly when using these devices. These yields range from 15-68% in different
studies. Factors impacting these yields include the patient’s ability to recognize and activate the
monitors.
Sources: BioTelemetry Website & Documents; American Heart Association
Event Recorder monitoring device
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Appendix 4 – Mobile Cardiac Monitoring
MCOT devices continuously record and automatically transmit cardiac data for a monitoring period 
up to 30 days
Description
• A Mobile Cardiac Monitoring is a cardiac monitoring method that uses a small portable device to
record a patient’s cardiac activity. The cardiac monitoring period for MCOT can range up to 30 days
• These devices automatically send data to monitoring centers when a cardiac anomaly is detected. In
contrast to the Traditional Holter and Event Recorders, MCOT provides real-time monitoring and
analysis. This is a more expensive monitoring method when compared to Traditional Holter and Event
devices.
Prescription
• MCOT devices may be prescribed when longer and continuous cardiac recording periods are needed.
MCOT devices have proven beneficial mainly in patients with unexplained syncope, Cryptogenic
Stroke and post ablation.
Cardiac Data Recording Process
• When a physician orders an MCOT device for a patient, they will also register the patient with their
cardiac monitoring provider. The patient will either have the electrodes connected while they are in the
office, or the MCOT device will be delivered to the patient’s home and the patient will connect the
electrodes themselves. In some devices, electrodes may be replaced by a patch similar to Extended
Holter devices. Electrodes, patches, and monitor’s battery may be replaced during the cardiac
monitoring period.
• Once the patient is ready, the monitoring system’s office will activate the MCOT device. A baseline
test will be collected from the patient, and the information will be sent wirelessly across the mobile
network. The data is transmitted to a 24-hour monitoring center via a mobile network and then
interpreted by cardiac technicians.
• The MCOT devices employ two-way wireless communications, enabling continuous transmission of
patient data to the monitoring centers and permitting physicians to remotely adjust monitoring
parameters and request previous ECG data from the memory stored in the monitor.
Diagnosis Yield
• Data collected using MCOT devices usually provide more information than Traditional Holter and
Event monitors. Diagnosis yields are also greater than all previous cardiac monitoring methods. In
some MCOT devices, these rates can range up to 88%.
MCOT monitoring device
Sources: BioTelemetry Website & Documents; Digirad






4. Mobile Cardiac Monitoring
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Appendix 5 – Implantable Loop Recorder
ILR devices monitoring time can range up to 3 years and they transmit data to cardiac technicians 
through a home monitor device
Description
• An Implantable Loop Recorder is a small implantable cardiac monitor (~size of an AA battery) that is
capable of automatically detecting and recording a number of abnormal heart rhythms.
• The device is inserted under the skin to the left of the patient’s breastbone and will continuously
monitor the patient’s heart rhythm for up to three years.
Prescription
• An ILR can help answer questions about the patient’s heart that other heart-monitoring devices do not
provide. It allows for long-term heart rhythm monitoring.
• It can capture information that a standard electrocardiogram, Traditional Holter or Event monitor miss
because some heart rhythm abnormalities occur infrequently. It allows physicians to reach a definite
diagnosis.
Cardiac Data Recording Process
• Patients need to undergo a minor surgical procedure to place the ILR.
• Patient Assistant: Patients can still record symptoms manually using the Patient Assistant device. To
make a symptomatic recording, the patient should hold the Patient Assistant over the ILR device and
press the button. The ILR is able to record the heart rhythm for up to 6 minutes, 30 seconds before the
button on the Patient Assistant is pressed and 1 minute after. This should give the patient plenty of
time to use the Patient Assistant after the onset of symptoms. These recordings are stored within the
ILR, which can store up to 4 symptom episodes before the memory is full. To reset the memory and
allow to make more recordings, the data will need to be sent to the Heart Devices Team/Cardiac
Technicians using the Home Monitor.
• Home Monitor: This is a bedside monitor that communicates with the patient’s ILR device and sends
information to the Heart Devices Team at a given hospital/data analysis center. All automatic
recordings are sent daily, however, symptomatic recordings made using the Patient Assistant need to
be sent by the patient. The monitor uses a cellular signal and is plugged into a power outlet.
Diagnosis Yield
• Yields are usually higher than Traditional Holter and Event recorders. According to studies, these can
range up to 73%. The majority of diagnosis is reached in the first six months of the monitoring period.
Data is automatically 
transmitted from the 
ILR to the HM on a 
daily basis
Manually recorded 
symptoms must be 
manually transmitted 
to the HM
Patients can manually 
record symptoms using 
the PA device
Data is transmitted from the HM to 
Hospitals/Cardiac Labs to be 
analyzed by cardiac technicians




Sources: Guy’s and St Thomas’ NHS Foundation Documents; National Heart, Lung, and Blood Institute; Mayo Clinic






4. Mobile Cardiac Monitoring
5. Implantable Loop Recorder
6. Pacemaker
Appendix 6 – Pacemaker
Pacemakers are targeted to patients with already identified arrhythmias and they help to control 
abnormal heart rhythms through electric stimulus
Description
• A Pacemaker is a small device that is placed in the patient’s chest or abdomen to help control
abnormal heart rhythms.
• This device uses electrical pulses to prompt the heart to beat at a normal rate. If patient’s heart rhythm
is abnormal, the Pacemaker will direct the generator to send electrical pulses to the heart.
Prescription
• These devices are prescribed to patients with identified arrhythmias and are used to control and treat
them.
• The most common reasons for prescriptions are patients who have bradycardia and heart block.
Bradycardia is a heartbeat that is slower than normal. Heart block is a disorder that occurs if an
electrical signal is slowed or disrupted as it moves through the heart.
• Besides monitoring and controlling the heartbeat, they can relieve some arrhythmias symptoms, such
as fatigue and fainting.
How Pacemakers Work
• Placing a Pacemaker requires minor surgery. The surgery usually is done in a hospital or special
heart treatment laboratory.
• The electrodes detect the patient heart's electrical activity and send data through the wires to the
computer in the generator. If the heart rhythm is abnormal, the computer will direct the generator to
send electrical pulses to the heart. The pulses travel through the wires to reach the heart.
• Doctors can program the Pacemaker's computer with an external device. He/she does not have to
use needles or have direct contact with the Pacemaker. Pacemakers have one to three wires that are
each placed in different chambers of the heart, as illustrated. Pacemaker placement in the patient’s heart
Sources: National Heart, Lung, and Blood Institute; Mayo Clinic
Device Key Information Illustration
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Appendix 7 – Players in the Remote Cardiac Monitoring Market
Many players intervene in the process of delivering cardiac monitoring services to patients
Market Dynamics Remote Cardiac Monitoring Market Dynamics Description
Raw Materials Suppliers
• Suppliers provide the necessary components to manufacturers to produce cardiac monitoring devices. The number of suppliers is limited and the
process to qualify suppliers is lengthy, which increases the supplier power.
• Suppliers’ components are subject to testing of performance before a purchasing agreement is signed. Suppliers also have to comply with FDA
regulatory requirements and are subject to potential regulatory inspections and stoppages.
1
Cardiac Device Manufacturers
• Manufacturers buy raw materials and components from suppliers and then produce a diversified range of cardiac monitoring devices, including
Traditional Holter, Event, and MCOT monitors.
• Given that these monitors are classified as medical devices, manufacturers are subject to extensive FDA regulation. FDA regulations govern the
manufacturing, labeling, promotion, distribution, importing, exporting, shipping, advertising, promotion, and sale of these devices. In some cases,
manufacturers are also the entities providing the monitoring and analysis services of the cardiac data collected with their devices.
2
Cardiac Device Providers & Monitoring Centers
• These entities make available cardiac monitoring devices to doctors and patients and monitor and analyze the cardiac data collected. When these
entities do not produce their own devices, they buy them from cardiac devices manufacturers.
• When doctors/physicians prescribe a given cardiac monitoring treatment, cardiac devices providers lend the cardiac monitors to patients and then
collect and analyze the cardiac data. This data is analyzed in monitoring centers, in some cases operating for 24 hours, by specialized cardiac
technicians. They report urgent events and make available final analyzes to physicians.
• These entities get reimbursed by Insurance Plans and Government Healthcare Plans. Cardiac devices providers are not allowed under Federal and
anti-kickback laws to pay or receive anything of value to induce prescription or referral of reimbursed products or services. They are also limited in
terms of financial arrangements which they may have with healthcare professionals in a position to purchase, recommend or refer patients for their
cardiac monitoring services or other products.
3
Physicians
• Physicians prescribe cardiac monitoring treatments to patients, which are rendered by the cardiac device providers and monitoring centers. During
the cardiac monitoring period, physicians may be alerted by the monitoring centers about patients’ urgent cardiac events.
• When the monitoring period is over, physicians receive the analysis report from the monitoring centers.
4
Patients
• Patients are the end-users of the cardiac monitoring devices. They receive them either during their medical appointment or at their home via post
office delivery. When the cardiac monitoring period is over, patients have to return the monitoring devices back to physicians or via post office.
5
Medicare & Other Payors
• Medicare and other insurance plans reimburse cardiac device providers and monitoring centers for the cardiac monitoring services rendered.




















In some cases, players consolidate these two operations
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Appendix 8 – Competitive Landscape
BioTelemetry faces direct competition from companies offering MCOT or Extended Holter in 













BioTelemetry, Inc. 399 ✓ ✓ ✓ ✓ ✓ ✓
iRhythm 182 ✓ ✓
SHL Telemedicine, Ltd. 42 ✓ ✓
Bardy Diagnostics 27 ✓ ✓
Preventice Solutions 5 ✓ ✓ ✓ ✓
CardioDiagnostics, Inc. 4 ✓ ✓
Abbott Laboratories 30,935 ✓ ✓ ✓
Medtronic plc 30,666 ✓ ✓




BIOTRONIK SE 700 ✓ ✓ ✓
InfoBionic, Inc. 8 ✓
Personal MedSystems 4 ✓
Qardio, Inc. 1 ✓
Schiller AG - ✓
• The patient monitoring market is highly fragmented
with large and small competitors.
• BioTelemetry faces direct competition from companies
that offer MCOT or Extended Holter, both in
combination with a monitoring service.
• The direct competition comprises five companies,
whereas iRhythm is the largest one in terms of
revenue.
• Preventice Solutions offers a similar product portfolio
to BioTelemetry.
• Besides the direct competition, large healthcare
companies, such as Abbott and Medtronic compete on
the Holter and Implant business.
• Large companies have a better sales channel and
could, therefore, enter the MCOT and service market.
• Abbott decided not to offer a monitoring service for its
continuous glucose monitoring device because they
want patients to focus on their disease1.
• Larger companies participate in the MCOT market by
M&A activities. Boston Scientific Group holds a
minority stake in Preventice Solutions since 2015.





Appendix 9 – BioTelemetry’s Intellectual Property













MCOT OS MCOT 16 32
Australia, Canada, China, Europe (European Patent Office1), Japan, 
US
2026
CardioNet C5 (Monitor), MCOT C3, MCOT1 Lead 
Patch, MCOT3 Lead, and ECAT2
MCOT 20 38
Australia, Canada, China, Europe (European Patent Office1), Japan, 
US
2026
Fusion Event 6 13 Australia, Canada, Europe (European Patent Office1), US 2025
CK100 CardioKey2 Holter 8 11
Canada, China, Europe (European Patent Office1), India, Hong Kong, 
Japan, Korea, US
2030
ER920W Event 5 13 Australia, Canada, Europe (European Patent Office1), US 2022




Australia, Canada, China, Europe (European Patent Office1), Hong 
Kong, Japan, US
2032
Other (e.g. Data Control, Data Monitoring and 
Transmission, Access to monitoring, etc.)
Other 6 13 - 2021
Total BioTel Heart Patents 63 134 ~2026
BioTel Care Handheld Blood Glucose Monitoring Device BGM 2 - US 2034
Total BioTel Care Patents 2 - ~2034
24
Notes: 1Countries covered under the European Patent Office include: Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein,
Lithuania, Luxembourg, Macedonia, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom; 2CardioKey is BioTelemetry’s next generation
of Traditional Holter devices. Sources: BioTelemetry Website & Documents; United States Patents and Trademark Office
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Appendix 10 – BioTel’s M&A Activity





Acquired Firm Deal Rationale & Description
• BioTelemetry acquired full control of Geneva, a firm that provides remote monitoring for implantable cardiac devices utilizing a proprietary cloud-based platform.
• Geneva enables BioTelemetry to remotely monitor a physician’s patients with implantable cardiac devices, such as Pacemakers, Defibrillators and Loop Recorders.
• Geneva’s platform provides physicians a single portal to order patient monitoring, review monitoring results and request routine device checks, helping drive
significant in-office efficiencies and patient compliance.
• The firm expects Geneva to contribute at least $10mn of revenue with a gross margin in excess of 60%.
• This acquisition costed BioTelemetry $45.9mn in cash.
Geneva
• BioTelemetry acquired the remaining outstanding equity (76.2%) of ADEA Medical.
• ADEA Medical is a Sweden company that provides cardiac monitoring in northern Europe.
• Total consideration paid at closing amounted to $0.2mn in cash and 50,000 shares of BioTelemetry’s common stock valued at $2.1mn.
ADEA Medical
• BioTelemetry acquired full control of LifeWatch at the end of 2017, a developer of MCOT devices.
• BioTelemetry gained access to a range of MCOT devices that allowed the firm to strengthen its position as the leader in wireless medicine, creating the foremost
connected health platform, significantly enhancing its ability to improve quality of life and reduce the cost of care.
• Total consideration paid at closing amounted to 3,694,432 BioTelemetry’s common shares with a fare value of $119.4mn and cash in the amount of $173.5mn.
• Asset Purchase Agreement in April 2016 for all products and total indications under development in the ePatch division.
• BioTelemetry expected to generate future cost savings and to acquire control in products needed for the next generation of its MCOT devices.















• VirtualScopics is a leading provider of clinical trial imaging solutions.
• BioTelemetry expected to expand its existing clinical research offerings and to gain further access to established customer relationships.





• BioTelemetry acquired assets primarily consisted of customer relationships.
• Total consideration paid at closing amounted to 3.8mn in cash. The purchase price also includes a potential earn-out payment of $2.0mn, which is contingent on the




• Telcare respective diabetes care management company (now it operates under the name of BioTel Care).
• BioTelemetry also acquired the control of Telcare Medical Supply, a subsidiary of Telcare.
• BioTelemetry expected to apply the firm’s expertise in Remote Monitoring to the Diabetes market and to increase its presence in the Digital Population Health
Management market.







Sources: BioTelemetry Annual Reports & Market News
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Appendix 11 – Cardiac Monitoring Devices Portfolio
















Product Name DigiTrak XT Holter DL800 ePatch wEvent MCOT 3L MCOT Patch ILR
Monitoring Period 24-48h 24-72h 3-14 days Up to 30 days Up to 30 days Up to 30 days 3 years
Description
Lightweight compact 
device that utilizes 
digital “flash memory” 
technology and 
provides a continuous 
diagnostic 3-channel 
EKG. The stored data 
is mailed or sent 
electronically to 
BioTel Heart.
Continuous recording of 
ambulatory ECG data 
and the ability to detect 
and record Pacemaker 
pulses. The monitor has 
a built-in electronic 
diary for symptom 
correlation and a 
removable flash card 




storing of heartbeats 
that are analyzed by 
certified cardiac 
technicians at BioTel 
Heart. 
The patient should 
write his/her 
symptoms and the 
feelings in the diary.
Non-looping, looping 
and auto-trigger 
monitors to accurately 
detect arrhythmia. It 
offers an accurate 
arrhythmia detection 






with automatic event 
detection and wireless 
transmission.
It is a 3-channel real-
time detection device 
that provides three 
distinct views of the 
heart for more specific 
and sensitive 
diagnostic value. 
The MCOT system 
conducts a beat-by-beat 
analysis of the patient’s 
heart activity and 
automatically transmits 
certain abnormal beats 
to the certified cardiac 
technicians at BioTel 
Heart. 
ILR monitors are 
implanted just under the 
skin of the chest for 
cardiac monitoring.
BioTelemetry does not
manufacture or sell 
ILR products. 
However, the firm 
provides monitoring
services for these 
products.
Diagnosis Yield 5-18% 5-18% 60% 15-68% 88% 88% 9-73%
Healthcare Product Portfolio
26
Sources: BioTelemetry Website & Documents
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• BioTelemetry’s MCOT devices have a competitive advantage over other cardiac monitoring
devices. These devices have the highest diagnostic yield among a wide range of cardiac
monitors, the highest turnaround time, and the highest patient compliance.
• The algorithms used in these MCOT devices maintain US Food and Drugs Administration
clearance, the authority which regulates these cardiac monitoring devices.
• According to BioTelemetry, its MCOT devices have proven to be nearly 3x superior at
detecting clinically significant arrhythmias when compared to other cardiac monitoring
devices, such as LOOP event monitors. BioTelemetry claims that its MCOT devices are the
most accurate mobile arrhythmia detection devices available.
• MCOT devices also proved to have a 5x greater cumulative probability (after 20 cumulative
days) of detecting post-stroke atrial fibrillation after a stroke happened when compared to
Implantable Loop Recording devices.
• These claims have been validated with over 40 scientific publications and abstracts that
confirm these devices’ utility. The MCOT devices have a 13x return in cost savings when
compared to Holter and Event technology.
• These scientific advantages may lead physicians and cardiologists to further prescribe
these devices, as these monitors have a higher diagnosis yield which can prevent future
patients’ strokes and other cardiac diseases.
Appendix 12 – MCOT Device Overview
BioTelemetry’s MCOT devices have a clear competitive advantage over other cardiac monitoring 
devices
These advantages have led to a significant increase 
in patient volume and consequently to a double-digit 
growth in revenue in 2018.
Sources: BioTelemetry Website & Documents
Mobile Cardiac Outpatient Telemetry
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• Medicare Service: Medicare is a federally-funded, national
health insurance program administered by Centers for Medicare
and Medicaid Services, providing coverage to Americans who
are 65 years of age or older, certain younger people with
disabilities, and individuals with end-stage renal disease. There
are several payment systems within the Medicare program,
including payment for inpatient hospital services, outpatient
hospital services, ambulatory surgery centers, home health,
physicians, and skilled nursing. The payment system that suits
BioTelemetry is Physician Payment.
• Physician Payment: Physicians receive payment for each
Current Procedural Terminology procedure code based on a fee
schedule called the Medicare Physician Fee Schedule. The
Physician Fee Schedule is based on a scale of national uniform
values for all physician services, commonly referred to as the
Resource-Based Relative Value Scale.
• Current Procedural Terminology: The CPT codes offer doctors
and health care professionals a uniform language for coding
medical services and procedures to streamline reporting,
increase accuracy and efficiency. The CPT terminology is the
most widely accepted medical nomenclature used across the
country to report medical, surgical, radiology, laboratory,
anesthesiology, genomic sequencing, evaluation and
management (E/M) services under public and private health
insurance programs.
Appendix 13 – Reimbursement Rates Computation
CMS sets the reimbursement rates for Medicare, which are adjusted geographically
• The CMS is the entity responsible for setting the reimbursement
rates on an annual basis. These rates are computed through the
following formula:
1. Relative Value Units:
• Work RVU: Reflects the relative time and intensity associated with
furnishing a Medicare PFS service.
• Practice Expense RVU: Reflects the costs of maintaining a
practice (such as, renting office space, buying supplies and
equipment, and staff costs).
• Malpractice RVU: Reflects costs of malpractice insurance.
2. Geographic Practice Cost Indices: Each of the three RVUs are
adjusted to account for geographic variations in the costs of
practicing medicine in different areas within the US. These
adjustments are called GPCIs, and each kind of RVU component
has a corresponding GPCI adjustment.
3. Conversion Factor: To determine the payment rate for a
particular service, the sum of the geographically adjusted RVUs is
multiplied by a CF in dollars. The statute specifies the formula by







Physician documentation in patient medical 
record
Transfer of information to billing/coding 
department
Selection of appropriate diagnosis and 
procedure codes
Submission of billing form to Medicare 
Administrative Contractor
Review of coding and physician 
documentation for medical necessity
Payment from MAC to hospital or physician 














Sources: Boston Scientific Billing and Coding Guide; CMS Documents
Medicare & CPT codes Medicare Payment Process Reimbursement Rates Computation
28
January 2020
Appendix 14 – BioTelemetry’s Reimbursement Rates Overview 
BioTelemetry operates mainly in San Francisco, which has one of the the highest reimbursement 








Reimbursement Rates (in $) – Facility Rates1




External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage;
scanning analysis with report.




Scanning analysis with report – technical component. Malvern, PA 316.19 317.77 319.36 333.7 335.37 336.21
93229 MCOT
External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real-
time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with
ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30
days; technical support for connection and patient instructions for use, attended surveillance, analysis, and
transmission of daily and emergent data reports as prescribed by a physician or other qualified health care
professional.
San Francisco, CA 919.12 946.96 1016.78 987.14 983.04 950.69
93268 Event
External patient and, when performed, auto-activated electrocardiographic rhythm derived event recording
with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended
monitoring; includes transmission, review, and interpretation by a physician or other qualified health care
professional.
San Francisco, CA 275.53 280.84 280.66 273.97 272.11 266.20
93288 Pacemaker
Interrogation device evaluation (in person) with analysis, review, and report by a physician or other qualified
health care professional, includes connection, recording, and disconnection per patient encounter; single,
dual, or multiple lead Pacemaker system3.
San Francisco, CA 21.34 22.11 21.53 22.57 22.57 30.24
93298 ILR
Interrogation device evaluation(s), (remote) up to 30 days; subcutaneous cardiac rhythm monitor system,
including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other
qualified health care professional.
San Francisco, CA 30.41 30.63 30.52 30.8 30.6 30.15
Notes: 1Facility rates refer to the fee schedule amount when a physician provides this service in a facility setting, such as a hospital or Ambulatory Surgical Center. These rates are equal to the Non-Facility fees for the listed codes; 2Rates for 2015 are the 
revised ones, updated in the second half of 2015. This update did not impact significantly the non-revised rates; 3Rates for Pacemaker refer only to the Technical Component of the service, which excludes the service rendered by doctors (e.g. connection 
of the Pacemaker). Sources: CMS Physicians Fee Schedule; Kerrisdale Capital Equity Report
BioTelemetry monitors its Medicare Patients in the CardioNet monitoring center in San Francisco, CA with the exception of its Extended Holter services, for which the firm monitors the data in its
monitoring center in Malvern, PA. Medicare reimbursement rates vary across states and in some cases within each state – BioTelemetry is reimbursed based on the location of its monitoring centers.
Medicare Reimbursement Rates for Remote Cardiac Monitoring Services
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Appendix 15 – Traditional Holter and Extended Holter Reimbursement Rates
A significant reduction in Extended Holter reimbursement rates is expected by 2023
Monitoring, Billing & Reimbursement Rates
• A Traditional Holter requires about 20 minutes of technician time1.
• BioTel monitors and analyzes its Traditional Holter cardiac data in its monitoring center in San
Francisco, CA. In 2019, the San Francisco, CA, Traditional Holter reimbursement rate was ~32%
greater than the national average.
• San Francisco Traditional Holter rate has been decreasing for 4 consecutive years, being 2019 the
year with the greatest YoY decrease (3.6% vs. 2.1%, 2.0%, and 0.4% in 2018, 2017, 2016,
respectively).
• BioTel’s Traditional Holter services are billed under the 93226 CPT code, which refers to the external
electrocardiographic recording up to 72 hours by continuous rhythm recording and storage and
scanning analysis with a report.
• 2020 proposed rate: Despite the increase in the conversion factor and in the Holter national average
reimbursement rate, it is expected San Francisco’s rate to decrease by 0.1% in 2020 due to the






2014 2015 2016 2017 2018 2019 2020E
Reimbursement Rates, In $
San Francisco, CA US National Average
Monitoring, Billing & Reimbursement Rates
• An Extended Holter requires about 40-60 minutes of analysis performed by a cardiac technician1.
• BioTel operates its Extended Holter services in its monitoring centers in Malvern, PA. Pennsylvania
is also one of the states with the highest reimbursement rates for this kind of services. This rate was
set by Novitas, the MAC responsible for PA state. In 2019, the reimbursement rate was $336.212.
• BioTel’s Extended Holter services are billed under the 0297T CPT code, which refers to the
scanning analysis with report of the cardiac data collected from patients. This is a Category III
code, which means it is temporary – temporary codes are usually used in new
methods/technologies yet to be proved worthwhile for patients.
• However, the 0297T code is expected to be transitioned to Category I the latest by 20231,
which will mean a significant reduction in reimbursement rates for Extended Holter services.
Category I reimbursement rates for the permanent code are expected to be similar to the Traditional
Holter devices, which would mean a reduction of ~86% when compared to 2019 rates.
• Reimbursement rates for temporary codes are not defined by the CMS. Instead, the Medicare
Administrative Contractor is the one responsible for setting these rates on a “contractor priced”
method. Currently, these rates vary significantly from state to state and from MAC to MAC.
• Despite this significant reduction in reimbursement rates, it is expected a not so significant





2014 2015 2016 2017 2018 2019
Reimbursement Rates, In $
Pennsylvania, PA
Sources: 1Kerrisdale Capital Equity Report; 2Novitas Physicians Fee Schedule; CMS Physicians Fee Schedule
Traditional Holter Devices Extended Holter Devices
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Appendix 16 – MCOT and Event Recorder Reimbursement Rates
MCOTs have the highest reimbursement rate among all BioTelemetry’s services
Monitoring, Billing & Reimbursement Rates
• BioTel’s Event services are billed under the 93268 CPT code, which refers to the transmission,
review, and interpretation by a physician or other qualified health care professional of the patient’s
cardiac data recorded for a period up to 30 days.
• BioTel monitors and analyzes Event cardiac data in its monitoring center in San Francisco, CA. In
2019, the San Francisco, CA, Event reimbursement rate was ~30% greater than the national
average reimbursement rate.
• San Francisco Event rate has been decreasing for four consecutive years, being 2017 the year with
the highest YoY decrease (2.4% vs. 2.2%, 0.7% and 0.1% in 2019, 2018 and 2016, respectively).
• 2020 proposed rate: Event rate for San Francisco is expected to decrease by 0.2% in 2020, mainly






2014 2015 2016 2017 2018 2019 2020E
Reimbursement Rates, In $
San Francisco, CA US National Average
Monitoring, Billing & Reimbursement Rates
• BioTel’s Mobile Cardiac Outpatient Telemetry services are billed under the 93229 CPT code, which
refers to the recording, transmission, patient surveillance, review, and interpretation by a physician or
other qualified health care professional of the cardiac data recorded for a period up to 30 days.
• BioTel monitors and analyzes its MCOT cardiac data in its monitoring center in San Francisco, CA.
In 2019, the San Francisco reimbursement rate was ~32% greater than the national average
reimbursement rate for MCOT services.
• San Francisco MCOT rate has been decreasing for 3 consecutive years, being 2019 the one with
the highest YoY decrease (3.3% vs. 0.4% and 2.9% in 2018 and 2017, respectively).
• In 2009, MCOT’s CPT code was transitioned from Category III to Category I, which led to a
significant decrease in the reimbursement rate for that year. Prior to 2009, BioTelemetry
reimbursement rates for MCOT services were set by Highmark Medicare Services (now Novitas), the
MAC responsible for the CA state. When CMS defined the new rate, the national average
reimbursement rate decreased ~33%, from $1,123 to $754. After this, BioTelemetry decided to
move its monitoring center to San Francisco, CA to take advantage of higher reimbursement rates1.
• 2020 proposed rate: MCOT rate for San Francisco is expected to increase by 0.1% in 2020. This







2014 2015 2016 2017 2018 2019 2020E
Reimbursement Rates, In $
San Francisco, CA US National Average
Sources: 1Kerrisdale Capital Equity Report; CMS Physicians Fee Schedule
MCOT Devices Event Devices
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Appendix 17 – Pacemaker and ILR Reimbursement Rates 
Pacemaker rates with 34% increase in 2019, ILR rates keep decreasing for two consecutive years
Monitoring, Billing & Reimbursement Rates
• BioTel’s ILR services are prescribed under the 93298 CPT code, which refers to the analysis of
recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health
care professional.
• BioTel monitors and analyzes ILR cardiac data in its monitoring center in San Francisco, CA. In
2019, the San Francisco, CA, Event reimbursement rate was ~11% greater than the national
average reimbursement rate.
• San Francisco ILR rate has been decreasing for 2 consecutive years, being 2019 the one with the
highest YoY decrease (1.5% vs. 0.6% in 2018).
• 2020 proposed rate: Rate for ILR services in San Francisco is expected to increase by 2.2% when
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San Francisco, CA US National Average
Monitoring, Billing & Reimbursement Rates
• BioTel’s Pacemaker services are prescribed under the 93288 CPT code, which refers to the analysis,
review and report by a physician or other qualified health care professional of the cardiac data
collected.
• BioTel monitors and analyzes Pacemaker cardiac data in its monitoring center in San Francisco,
CA. In 2019, the San Francisco, CA, Event reimbursement rate was ~31% greater than the national
average reimbursement rate.
• San Francisco Pacemaker rate increased by 34% from 2018 to 2019, the highest growth in the past
5 years.
• 2020 proposed rate: Rate for Pacemaker services in San Francisco is expected to increase in 2020
by ~24% when compared to 2019. Besides the increase in the conversion factor, this growth is also





2014 2015 2016 2017 2018 2019 2020E
Reimbursement Rates, In $
San Francisco, CA US National Average
Sources: CMS Physicians Fee Schedule
Pacemaker Monitoring ILR Monitoring
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• BioTel Care Connected Blood Glucose Monitoring is the first cellular-enabled diabetes management solution that
connects people with diabetes and their care team. This remote monitoring sends messages and reminders along
with personalized education, and it keeps the care team in the loop with timely updates.
• It is to be used by diabetes patients and it can be prescribed by physicians. It is available for diabetes types 1 and 2.
• It offers easy monitoring of patients, reporting and info sharing – beyond the office – to help patients stay on
track and engaged in their well-being. With timely insights and two-way messaging, office visits can focus on
important opportunities for proactive care.
• How it Works: BioTel Care monitoring is not Wi-Fi dependent and there is no need for users to have a cell phone,
app, USB cords or additional hardware. Patients do not have to enter data. The blood glucose monitor
automatically transmits readings to BioTelemetry’s secure cloud. BioTel Care does it automatically anywhere
there is cellular connectivity. There are no data transmission charges.
• Each time patients want to test their blood they should use an included test strip. Immediately after taking a blood
glucose reading, patients receive a personalized message on the meter to support their health and reinforce their
health professional’s advice.
• In response to specific levels of blood glucose readings, triggered messages can be automatically generated.
• The information your meter provides enables your health professional to connect with you through the device, cell
phone, or email. For people with diabetes, at the touch of a finger, there are multiple educational tools all designed to
support patient health.
• This product is designed to provide a price competitive alternative to health insurance coverage that allows
individuals to avoid the hassle of submitting claims.
Appendix 18 – BGM Device
BioTelemetry’s Blood Glucose Monitoring connects patients and care team in real time 
BioTel Care is BioTelemetry’s business dedicated to patient remote monitoring and analysis of blood glucose for diabetes population and health management. BioTel Care is the first FDA-cleared
cellular-connected blood glucose meter.
The Blood Glucose Monitoring is 
available in two subscription 
methodologies:
• Annual Subscription (1 year) with 
Monthly Charge of $24.99 = 
$299.88/year
• Monthly Subscription: $99 month 1 for 
meter; $24.99 per month thereafter = 
$373.89/year
Sources: BioTelemetry Website & Documents
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